Domestic animal endocrinology最新文献

{"title":"Changes in cortisol, cortisone and 11β-hydroxysteroid dehydrogenase type II activity in saliva during pregnancy and lactation in sows","authors":"M. Botía ,&nbsp;D. Escribano ,&nbsp;F. Tecles ,&nbsp;S. Martínez-Subiela ,&nbsp;J.J. Cerón ,&nbsp;M. López-Arjona","doi":"10.1016/j.domaniend.2024.106875","DOIUrl":"10.1016/j.domaniend.2024.106875","url":null,"abstract":"<div><p>The activity of the enzyme 11β-hydroxysteroid dehydrogenase type II, which can be estimated by the combined measurement of cortisol and cortisone, is gaining importance as a marker for the assessment of stress in pigs. The aim of this study was to investigate the activity of this enzyme and the salivary concentrations of cortisol and cortisone in pigs during pregnancy, farrowing and lactation and to compare it with other stress-related biomarkers such as CgA, S100A12 and alpha-amylase. Salivary cortisol concentrations and 11β-hydroxysteroid dehydrogenase isoenzyme type 2 activity decreased after farrowing, while cortisol concentrations increased. Enzyme activity did not show significant correlations with any of the other stress-related biomarkers measured in this study. Overall, the results of this report indicate a different regulation of 11β-HSD type II activity and of cortisol and cortisone during pregnancy and lactation, which should be considered when evaluating these analytes in saliva during these periods.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106875"},"PeriodicalIF":1.9,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0739724024000389/pdfft?md5=7a3f8d2d88224ea8c824d228562044f7&pid=1-s2.0-S0739724024000389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141700394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The glucagon-receptor antagonist MK-3577 reduces glucagon-stimulated plasma glucose and insulin concentrations in metabolically healthy overweight cats","authors":"J Mott ,&nbsp;C Celly ,&nbsp;R Glock ,&nbsp;C Gilor","doi":"10.1016/j.domaniend.2024.106874","DOIUrl":"10.1016/j.domaniend.2024.106874","url":null,"abstract":"<div><p>The role of glucagon disturbances in diabetes mellitus is increasingly recognized and, hence, glucagon antagonism might aid in treatment of hyperglycemia and other metabolic disturbances. The aim of this study was to assess the pharmacokinetics of the glucagon receptor antagonist MK-3577 and its effect on plasma glucose, insulin, and glucagon concentrations in healthy cats. In a cross-over placebo-controlled study, 5 purpose-bred cats were treated with either Placebo, MK-3577 (1 mg/kg), or MK-3577 (3 mg/kg). Glucose, insulin and glucagon concentrations were measured at 0, 15, 225, 240 min post-treatment administration. Glucagon (20 mcg/kg, IM) was administered at 240 min and glucose and insulin were measured at 255, 265, 275, 285 and 300 min. Plasma MK-3577 concentrations peaked at 4.2 and 3.2 hours after 1 and 3 mg/kg dosing with a half-life of 14.8h and 15.5h respectively. Baseline glucose, insulin and glucagon concentrations did not differ significantly between treatment groups. At a dose of 3 mg/kg, MK-3577 blunted the glucagon-stimulated rise of glucose (<em>p=</em>0.0089) and insulin (<em>p=</em>0.02). Similar trends were observed with MK-3577 at the 1 mg/kg dose but the effect was smaller, and not significant. In conclusion, the GRA MK-3577 has a pharmacokinetic profile suitable for diminishing the glucagon-induced rise of glucose and insulin in healthy cats.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106874"},"PeriodicalIF":1.9,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine fibroblast growth factors in domestic animals","authors":"Emily J. Brinker ,&nbsp;Michael R. Hardcastle ,&nbsp;Keren E. Dittmer ,&nbsp;Emily C. Graff","doi":"10.1016/j.domaniend.2024.106872","DOIUrl":"10.1016/j.domaniend.2024.106872","url":null,"abstract":"<div><p>Fibroblast growth factors (FGFs) are a group of structurally homologous yet functionally pleiotropic proteins. Canonical and intracellular FGFs have primarily autocrine or paracrine effects. However, the FGF19 subfamily, composed of FGF15/19, FGF21, and FGF23, act as endocrine hormones that regulate bile acid, metabolic, and phosphorus homeostasis, respectively. Current research in human and rodent models demonstrates the potential of these endocrine FGFs to target various diseases, including disorders of inherited hypophosphatemia, chronic liver disease, obesity, and insulin resistance. Many diseases targeted for therapeutic use in humans have pathophysiological overlaps in domestic animals. Despite the potential clinical and economic impact, little is known about endocrine FGFs and their signaling pathways in major domestic animal species compared with humans and laboratory animals. This review aims to describe the physiology of these endocrine FGFs, discuss their current therapeutic use, and summarize the contemporary literature regarding endocrine FGFs in domestic animals, focusing on potential future directions.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106872"},"PeriodicalIF":1.9,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0739724024000353/pdfft?md5=95b4cc62b1e98552fed88c7c5d9e54c4&pid=1-s2.0-S0739724024000353-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141717001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between post-ACTH cortisol and trilostane dosage in dogs with pituitary-dependent hypercortisolism","authors":"Fernanda Nastri Gouvêa ,&nbsp;Alessandra Martins Vargas ,&nbsp;Ednaldo Carvalho Guimarães ,&nbsp;Leandro Zuccolotto Crivellenti ,&nbsp;Caio Santos Pennacchi ,&nbsp;Hévila Dutra Barbosa de Cerqueira ,&nbsp;Luana de Oliveira Branco ,&nbsp;Natani Silva Reis ,&nbsp;Sofia Borin-Crivellenti","doi":"10.1016/j.domaniend.2024.106871","DOIUrl":"10.1016/j.domaniend.2024.106871","url":null,"abstract":"<div><p>Trilostane is the current treatment of choice for managing pituitary-dependent hypercortisolism (PDH) in dogs. While prescribing higher initial doses may elevate the risk of iatrogenic hypocortisolism, opting for more conservative approach could result in delayed disease control, since most individuals end up requiring dosage increases. The adrenocorticotrophin stimulation test (ACTHst), a widely recognized hormonal test for assessing adrenal function, is an essential tool for monitoring the pharmacological treatment of canine hypercortisolism (CH) that can also be used for diagnostic purposes. The aim of this study was to investigate the relationship between post-ACTH cortisol (cpACTH) at PDH diagnosis and the required trilostane dose for sign control and endogenous cortisol regulation in dogs, considering a hypothesis that higher serum cpACTH concentration would necessitate a higher trilostane dosage for disease management. Data for 43 dogs with PDH had their diagnostic cpACTH recorded and correlated to the trilostane dosage necessary to control clinical signs and achieve satisfactory cortisol levels (ideally 2-7 μg/dL). The odds ratio (p=0.042) suggests that dogs with cpACTH ≥ 27 μg/dL at diagnosis are 96% more likely to need a higher trilostane dosage for achieving satisfactory control of PDH. Thus, cpACTH was found to be associated with the final trilostane dose for controlling PDH in dogs.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106871"},"PeriodicalIF":1.9,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141710070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of PI3K/AKT/mTOR signaling pathway in the ovine liver and duodenum during early pregnancy","authors":"Hongxu Fang ,&nbsp;Xinxin Wang ,&nbsp;Zhongyue Wang ,&nbsp;Xiaoxin Ma,&nbsp;Leying Zhang,&nbsp;Ling Yang","doi":"10.1016/j.domaniend.2024.106870","DOIUrl":"https://doi.org/10.1016/j.domaniend.2024.106870","url":null,"abstract":"<div><p>The liver and intestine play a critical role in nutrient absorption, storage, and metabolism. The aim of this study was to evaluate expression pattern of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) signaling pathway that included PI3K, AKT1, mTOR, FoxO1, SREBP-1, PPARα, PTEN and FXR in the maternal liver and duodenum. Ovine livers and duodenums were sampled at day 16 of the estrous cycle, and at days 13, 16 and 25 of gestation, and RT-qPCR, western blot and immunohistochemistry analysis were used to detect mRNA and protein expression. The results showed that expression of PI3K, AKT1, p-mTOR, FoxO1, SREBP-1 and PTEN upregulated in the maternal liver, and PPARα upregulated in the duodenum. However, expression of FoxO1, SREBP-1 and PTEN in the duodenum downregulated during early pregnancy. In addition, expression levels of SREBP-1, PTEN and PPARα in the maternal liver, and PI3K in the duodenum peaked at day 13 of pregnancy. In addition, expression levels of PI3K, p-mTOR and FoxO1 in the liver, and AKT1 and p-mTOR in the duodenum peaked at day 16 of pregnancy. Nevertheless, expression levels of FXR both in the maternal liver duodenum downregulated at days 13 and 16 of pregnancy. In conclusion, early pregnancy regulated expression pattern of PI3K/AKT/mTOR signaling pathway in the ovine liver and duodenum in a pregnancy stage-specific and tissue-specific manner, which may be necessary for the adaptations in maternal hepatic nutrient metabolism and intestinal nutrient absorption early pregnancy.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106870"},"PeriodicalIF":1.9,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141485840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic inflammation decreases arcuate kisspeptin expression in male sheep","authors":"AN Renwick ,&nbsp;BK Whitlock ,&nbsp;CC Nestor ,&nbsp;JA Daniel ,&nbsp;L Strickland ,&nbsp;AS Lear ,&nbsp;M Adkins ,&nbsp;C Griffin ,&nbsp;A Esteller-Vico","doi":"10.1016/j.domaniend.2024.106868","DOIUrl":"10.1016/j.domaniend.2024.106868","url":null,"abstract":"<div><p>Lipopolysaccharide (LPS) from Gram-negative bacteria induces an immune response and impairs reproduction through suppression of gonadotropin releasing hormone (GnRH), subsequently luteinizing hormone (LH) secretion. While there is evidence that acute inflammation inhibits kisspeptin, little is known about the impact of chronic inflammation on this key reproductive neuropeptide in livestock species. Thus, we sought to examine a central mechanism whereby LPS suppresses LH secretion in sheep. Twenty wethers were randomly assigned to one of five treatment groups: control (CON; n=4), single acute IV LPS dose (SAD; n=4), daily acute IV LPS dose (DAD; n=4), daily increasing IV LPS dose (DID; n=4), and chronic subcutaneous LPS dose (CSD; n=4). On Days 1 and 7, blood samples were collected every 12 minutes for 360 minutes using jugular venipuncture. Following blood collection on Day 7, all animals were euthanized, brain tissue was perfused with 4% paraformaldehyde, and hypothalamic blocks were removed and processed for immunohistochemistry. On Day 1, LH pulse frequency was significantly lower (p=0.02) in SAD (0.25 ± 0.1 pulses/hour), DAD (0.25 ± 0.1 pulses/hour), DID (0.35 ± 0.1 pulses/hour), and CSD (0.40 ± 0.1 pulses/hour) compared to CON (0.70 ±0.1 pulses/hour). On Day 7, only DID animals (0.35 ± 0.1 pulses/hour) had significantly lower (p=0.049) LH pulse frequency compared to controls (0.85 ± 0.1 pulse/hour). Furthermore, only DID animals (33.3 ± 10.9 cells/section/animal) had significantly fewer (p=0.001) kisspeptin-immunopositive cells compared to controls (82.6 ± 13.6 cells/section/animal). Taken together, we suggest that daily increasing doses of LPS is a powerful inhibitor of kisspeptin neurons in young male sheep and a physiologically relevant model to examine the impact of chronic inflammation on the reproductive axis in livestock.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106868"},"PeriodicalIF":2.1,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141414968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incretin therapy in feline diabetes mellitus – A review of the current state of research","authors":"Nina Haller ,&nbsp;Thomas A. Lutz","doi":"10.1016/j.domaniend.2024.106869","DOIUrl":"https://doi.org/10.1016/j.domaniend.2024.106869","url":null,"abstract":"<div><p>Incretin hormones potentiate the glucose-induced insulin secretion following enteral nutrient intake. The best characterised incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which are produced in and secreted from the gut in response to nutrient ingestion. The property of incretins to enhance endogenous insulin secretion only at elevated blood glucose levels makes them interesting therapeutics for type 2 diabetes mellitus with a better safety profile than exogenous insulin. While incretin therapeutics (especially GLP-1 agonists, and more recently also GLP-1 / GIP dual agonists and other drugs that influence the incretin metabolism (e.g., dipeptidyl peptidase-4 (DPP-4) inhibitors)) are already widely used treatment options for human type 2 diabetes, these drugs are not yet approved for the therapy of feline diabetes mellitus. This review provides an introduction to incretins and feline diabetes mellitus in general and summarises the current study situation on incretins as therapeutics for feline diabetes mellitus to assess their possible future potential in feline medicine. Studies to date on the use of GLP-1 receptor agonists (GLP-1RA) in healthy cats largely confirm their insulinotropic effect known from other species. In diabetic cats, GLP-1RAs appear to significantly reduce glycaemic variability (GV, an indicator for the quality of glycaemic control), which is important for the management of the disease and prevention of long-term complications. However, for widespread use in feline diabetes mellitus, further studies are required that include larger numbers of diabetic cats, and that consider and test a possible need for dose adjustments to overweight and diabetic cats. Also evaluation of the outcome of GLP-1RA monotherapy will be neceessary.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106869"},"PeriodicalIF":2.1,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141313796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and gestation in Criollo mares: endocrine and metabolic profiles","authors":"Mateo Pardié ,&nbsp;Irene Kalpokas ,&nbsp;Francesca Freccero ,&nbsp;Carolina Castagnetti ,&nbsp;Ana Meikle","doi":"10.1016/j.domaniend.2024.106857","DOIUrl":"10.1016/j.domaniend.2024.106857","url":null,"abstract":"<div><p>The aim of this study was to determine the effect of body condition score (BCS) on metabolic and endocrine parameters in pregnant Criollo mares (<em>n</em>=41), which were categorized according to their BCS as obese (7 to 9 BCS, <em>n</em>=26) or normal (5 to 7, <em>n</em>=15). Blood samples were taken during gestation in 3 periods: between 3.5 and 5 months (I), 8 and 9 months (II) and in the last month of gestation (III). The data was analyzed in the statistical model by mixed procedures, including BCS, gestational period and their interaction as fixed effects. BCS was only different in period I, as normal mares increased their BCS in the later periods. Leptin concentrations were greater in obese mares when compared to non-obese mares during all sampling periods (<em>P</em>&lt;0.01), while glucose concentrations were also greater in the former group (<em>P</em>&lt;0.01) but only during the first sampling period. Insulin concentrations and homeostatic model assessment for insulin resistance (HOMA-IR) index were greater also in obese mares in periods I and III (<em>P</em>&lt;0.05). Adiponectin concentrations in period I were lower in obese mares (<em>P</em>&lt;0.05). Cholesterol concentrations increased during gestation, and obese mares tended to have greater concentrations than nonobese mares (<em>P</em>&lt;0.1). Triglyceride concentrations were not affected by group or gestational period. This study revealed adaptations in carbohydrate and lipid metabolism during gestation in mares. Several parameters are dependent on the degree of body fat reserves, which are reflected in the concentrations of biomarkers such as leptin and adiponectin. Insulin concentration in obese mares was higher than non-obese mares at the end of gestation, a similar profile was observed for HOMA-IR although cutoff values are yet still to be validated.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106857"},"PeriodicalIF":2.1,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GATA4: Regulation of expression and functions in goat granulosa cells","authors":"Kexin Gao ,&nbsp;Yeda Chen ,&nbsp;Peijie Wang ,&nbsp;Wenlin Chang ,&nbsp;Binyun Cao ,&nbsp;Liqiong Luo","doi":"10.1016/j.domaniend.2024.106859","DOIUrl":"10.1016/j.domaniend.2024.106859","url":null,"abstract":"<div><p>GATA4 plays a pivotal role in the reproductive processes of mammals. However, the research on GATA4 in goat ovary is limited. This study aimed to study the expression and function of GATA4 in goat ovary. Utilizing real-time PCR and western blot analysis, we studied the expression and regulatory mechanisms of GATA4 in goat ovary and granulosa cells (GCs). We found that GATA4 was expressed in all follicle types in the goat ovary, with significantly higher levels in GCs of larger follicles (&gt;3 mm) compared to those in smaller follicles (&lt;3 mm). Additionally, we demonstrated that human chorionic gonadotrophin (hCG) induced <em>GATA4</em> mRNA expression via the activation of PKA, MEK, p38 MAPK, PKC, and PI3K pathways <em>in vitro</em>. Our study also showed that hCG suppressed the levels of miR-200b and miR-429, which in turn directly target GATA4, thereby modulating the basal and hCG-induced expression of GATA4. Functionally, we examined the effect of siRNA-mediated <em>GATA4</em> knockdown on cell proliferation and hormone secretion in goat GCs. Our results revealed that knockdown of <em>GATA4</em>, miR-200b, and miR-429 suppressed cell proliferation. Moreover, knockdown of <em>GATA4</em> decreased estradiol and progesterone production by inhibiting the promoter activities of <em>CYP11A1, CYP19A1, HSD3B,</em> and <em>StAR</em>. Collectively, our findings suggest a critical involvement of GATA4 in regulating goat GC survival and steroidogenesis.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106859"},"PeriodicalIF":2.1,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased insulin-like growth factor 1 concentrations in a population of non-diabetic cats with overweight/obesity","authors":"D.D. Miceli ,&nbsp;A. Jaliquias ,&nbsp;M.F. Gallelli ,&nbsp;J.D. García ,&nbsp;C. Vecino ,&nbsp;J.P. Rey Amunategui ,&nbsp;G.A. Pompili ,&nbsp;I.M. Espiñeira ,&nbsp;J. Más ,&nbsp;O.P. Pignataro","doi":"10.1016/j.domaniend.2024.106858","DOIUrl":"10.1016/j.domaniend.2024.106858","url":null,"abstract":"<div><p>Feline hypersomatotropism (HST) is typically associated with diabetes mellitus (DM), whereas HST without concurrent DM has only been reported in a few cases. Weight gain may be observed in cats with HST. The aims of this study were to evaluate circulating insulin-like growth factor-1 (IGF-1) in non-diabetic cats with overweight/obesity, to screen this population for the presence of HST, and to assess whether there is a correlation between body weight/body condition score (BCS) and serum IGF-1 concentration in overweight/obese cats. In this prospective study, 80 overweight/obese cats from referral centers in Buenos Aires (Argentina) were evaluated. Serum IGF-1 was measured as part of the routine tests for overweight/obesity. Non-diabetic cats were included in the study if they had a BCS&gt;6/9. Twenty-nine cats were classified as overweight (BCS 7/9), whereas 51 were classified as obese (BCS 8-9/9). Median serum IGF-1 concentrations of cats with BCS 7/9, 8/9, and 9/9 were 570 ng/ml (range 123-1456 ng/ml), 634 ng/ml (range 151-1500 ng/ml), and 598 ng/ml (range 284-2450 ng/ml), respectively. There was a positive linear correlation between serum IGF-1 concentrations and body weight (r= 0.24, 95% CI 0.01-0.44 P=0.03), and between IGF-1 and BCS (r= 0.27, 95% CI 0.08-0.44 P=0.004). In total, 8.75% (95% confidence interval 3.6-17.2%) of the cats with overweight/obesity had IGF-1 concentrations &gt;1000 ng/ml. Pituitary enlargement was detected on computed tomography in 4/7 cases. These seven cats showed varying degrees of phenotypic changes consistent with acromegaly. A proportion of 8.75 % of overweight/obese non-diabetic cats from referral centers in Buenos Aires had serum IGF-1 concentration in a range consistent with HST in diabetic cats. Likewise, 5% of overweight/obese cats were likely to be diagnosed with HST, supported by evidence of pituitary enlargement. Serum IGF-1 concentrations were positively correlated with body weight and BCS in this population of cats. This study highlights the relevance of screening different populations of non-diabetic cats to increase the detection of HST/acromegaly.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106858"},"PeriodicalIF":2.1,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}